co-1686: third generation drug for egfr positive lung cancer patients
Published 10 years ago • 128 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
2:28
co-1686, a third generation drug for egfr positive lung cancer patients
-
4:10
3rd generation drug for acquired resistance in egfr lung cancer
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
3:07
third generation egfr tkis for acquired resistance
-
8:16
does gilotrif help egfr positive lung cancer patients?
-
2:00
choosing first line therapy in egfr mutations
-
3:28
should third generation egfr inhibitors be used before or after progression?
-
4:02
egfr resisters: an advocacy group - targeted therapies in lung cancer 2023
-
4:22
what is egfr in lung cancer? - 2022 program: targeted therapies forum
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
1:02
are egfr tkis (such as tarceva) effective in lung cancer patients who are wild type egfr?
-
1:59
what is egfr and the egfr mutation?
-
1:01
dr. philip bonomi: gefitinib and later generations of egfr inhibitors
-
5:22
egfr tkis and their side effects - 2022 program: targeted therapies forum
-
2:47
treating egfr patients after tarceva stops working
-
2:22
aegean trial: perioperative durvalumab for nsclc - onctalk lung 2023
-
9:26
adding avastin to tarceva help egfr positive lung cancer patients?
-
1:21
why are non-mutated egfr genes called "wild type?"
-
4:09
egfr mutations: uncommon treatment & insurance complications -2022 program: targeted therapies forum